"Melperone"

investigating classical dopamine receptor antagonists (trifluperidol, thioproperazine, phenothiazine, trifluoperazine, perphenazine, chlorpromazine, melperone) reported no definite effects and these should not be used [10]. Haloperidol, however, has been shown to be effective in several Level II studies [9, 10, 43, 44].Because of the potential to further slow down intended/voluntary movements and the fact

Melperone is ineffective in treating Parkinson's disease psychosis.

health claims data of the largest German health insurer from 2004 to 2010 and followed newly-diagnosed dementia patients aged 60 years and older into LTC, NH, and until death. Cox proportional hazards models were estimated to explore whether the risk of these outcomes differed between patients receiving haloperidol, melperone, risperidone, or quetiapine. In a cohort of 6,930 dementia patients who were ) was significantly higher for haloperidol-, melperone-, and risperidone- but not for quetiapine users (HR = 0.91; CI = 0.78-1.08). The excess mortality associated with haloperidol and melperone was greater among patients living in private households. In our study, APDs appeared to accelerate adverse health outcomes in German dementia patients. Differentiating between the effect of antipsychotic drug use among

, melperone, anisoperidone, benperidol and anisopirol against multiple targets associated with AD. Benperidol was found to be the best candidate drug interacting with different target proteins involved in AD.

, asenapine, blonanserin, brexpiprazole, cariprazine, carpipramine, clocapramine, clorotepine, clotiapine, clozapine, iloperidone, levosulpiride, lumateperone, lurasidone, melperone, mosapramine, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, reserpine, risperidone, sertindole, sulpiride, sultopride, tiapride, veralipride, ziprasidone, zotepine, pimavanserin, stepholidine

Development of orally disintegrating tablets comprising controlled-release multiparticulate beads. Melperone is an atypical antipsychotic agent that has shown a wide spectrum of neuroleptic properties, particularly effective in the treatment of senile dementia and Parkinson's-associated psychosis, and is marketed in Europe as an immediate-release (IR) tablet and syrup. An orally disintegrating tablet (ODT) dosage form would be advantageous for patients who experience difficulty in swallowing large tablets or capsules or those who experience dysphagia. Controlled-release (CR) capsule and ODT formulations containing melperone HCl were developed with target in vitro release profiles suitable for a once-daily dosing regimen. Both dosage forms allow for the convenient production of dose

Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-centre study. A double-blind study was carried out in 53 elderly patients in 6 geriatric nursing homes to assess the effectiveness of the neuroleptics, zuclopenthixol and melperon (flubuperone), in the relief of restlessness, aggressiveness and other such symptoms. The initial daily dose was 4 mg zuclopenthixol or 75 mg melperon, increased if necessary over the treatment period of 4 weeks. Assessments were made on entry and after 1, 2 and 4 weeks of treatment of the overall severity of illness and of individual symptoms. The results showed that there was significant improvement in the condition of patients in both treatment groups and a significant reduction in mean total as well as in the main single

A double-blind study of melperone and placebo in hospitalized chronic alcoholics in postintoxication phase. In a double-blind study in chronic alcoholics melperone (Buronil) was shown to significantly improve muscular and nervous tension, emotional lability, somatization, ability to sleep, anxiety, depression, paranoid ideation and presumed ability to work, but had no effect on alcoholic craving

Antiarrhythmic properties of a neuroleptic butyrophenone, melperone, in acute myocardial infarction. A double-blind trial. In vitro animal studies suggest melperone, a neuroleptic butyrophenone, to be a type III antiarrhythmic drug according to the classification of Vaughan Williams. It has no negative inotropic effect on cardiac muscle. A double-blind trial of 3 hours' duration was carried out with melperone and placebo in 26 patients admitted to the CCU with suspected acute myocardial infarction (AMI) and ventricular arrhythmias. Melperone, 50 mg i.v., was superior to placebo in reducing the total number of ventricular ectopic beats (VEB) as well as the number of minutes with either frequent, multifocal, R-on-T-type or runs of VEB. The reduction became statistically significant in the second

A double blind study with melperone and placebo in the treatment of chronic alcoholics. In a 2-wk randomized double blind study 60 chronic alcoholics were treated with either melperone (Buronil) or placebo. The patients were assessed daily using a scale including 4 items: tension, depression, craving and sleep. Statistically significant improvement was achieved in the placebo group only for "tension" and "sleep"; whereas, in the melperone group all four items improved significantly. Comparison between the groups revealed statistically significant superiority of melperone over placebo for the item "craving".

Effect of single oral doses of various neuroleptic drugs on salivary secretion rate, pH, and buffer capacity in healthy subjects. The effects of melperone, thioridazine, levomepromazine, and chlorprotixene on salivary secretion rate, pH, and buffer capacity was studied in eight healthy volunteers given single oral doses of placebo or 10, 25, and 50 mg of the drugs in a single-blind crossover design. Both resting and stimulated saliva samples were collected before and every hour for 6h after administration. All drugs reduced secretion rate and lowered pH and buffer capacity, mostly in a dose-dependent manner. The effects of levomepromazine and chlorprotixene were more pronounced than those of melperone and thioridazine.

A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward. Twenty schizophrenic women participated in a double-blind comparison of melperone (300 mg daily) and placebo lasting 4 weeks. All the patients received milieu treatment. Two patients in the melperone and four in the placebo group were removed from the study due to unsatisfactory therapeutic response. In the melperone group, there were significant reductions in psychotic morbidity. In the placebo group, there were occasional significant reductions of psychotic morbidity during but not at the end of treatment. The melperone-treated patients exhibited significantly lower morbidity scores than the placebo group after treatment for two and four weeks. The melperone group demonstrated

Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study. 60 anxious neurotic outpatients completed a double-blind comparative 2 week clinical study of the anxiolytic effect of melperone 10 mg t.i.d. and 25 mg t.i.d. versus placebo. The efficacy was assessed by the Hamilton Anxiety Scale and Clinical Global Impressions. At the end of the 1st and the 2nd week of treatment, the reduction in the Hamilton scores was significantly greater in the melperone groups than in the placebo group, but there was no significant difference in the improvement of the two melperone groups. Similar findings were true for the global assessment. The adverse effects recorded were generally mild and transient, tiredness being the most frequent in both the placebo

Effect of melperone, chlorpromazine, haloperidol, and diazepam on experimental anxiety in normal subjects. An attempt was made to evaluate tranquilizing effects of three neuroleptic drugs (10 and 50 mg melperone, 1 mg haloperidol, and 50 mg chlorpromazine) and diazepam (10 mg) on experimental anxiety in normal subjects. This was done by studying the effects of the drugs on the anticipatory autonomic (skin conductance) response evoked during aversive classical conditioning. Diazepam, 50 mg melperone, and chlorpromazine completely abolished the anticipatory response, decreased the number of conditioned and unconditioned responses, and decreased skin conductance level. Treatment with 10 mg melperone and haloperidol had no effect on the conditioned and unconditioned responses.

compared with melperone was safe and effective with regard to restlessness and aggressive behaviour in elderly patients.

Melperon premedication for cataract surgery. A comparison with diazepam. Given as a peroral premedicant for geriatric patients having cataract surgery under regional block, a butyrophenone neuroleptic melperon (15-30 mg, n = 50) ranked equally with diazepam (4-10 mg, n = 50), assessed using a qualitative subjective estimation of the patients' anxiety. The patients treated with melperon needed significantly fewer supplementations with intravenous drugs, to withstand the surgery, compared to those medicated with diazepam. Melperon is a compatible alternative, but its possible propensity to cause occasional arterial hypotension must be noticed.

three days: Group 1: received a single daily i.m. application of 4 mg/kg body weight Melperone. Group 2: received a single daily i.m. application of 2 mg/kg body weight Amperozide. Group 3: was treated orally (intranasally) with 2 mg/kg body weight Amphetamin in a single daily application. Group 4: untreated control. The following parameters were evaluated before the begin of the therapy (day 0-4 ). A: Occurrence of diarrhea in a group B: Food consumption per piglet per day C: Death of piglets per group After the begin of the therapy (day 5-32) D: Death of piglets per group E: Average daily feed intake per piglet The results showed that the Melperone and Amphetamin treatment was superior regarding all examined parameters when compared to Amperozide treatment and to the control group.